Petros Pharmaceuticals, Inc. (PTPI): Nasdaq/NYSE listing notice — Petros Pharma receives Nasdaq delisting notice; trading to move to OTC Markets

Petros Pharmaceuticals, Inc.

Delisting due to failing minimum equity, bid price ($1.00), and public interest concerns from Feb 2025 offering.
Trading suspended on Nasdaq at open May 22, 2025; expected to trade on OTC Markets under PTPI.
Company has 15 days to appeal to Nasdaq Listing Council; appeal stays Form 25 but not suspension.
No assurance that Listing Council will grant continued listing on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Petros Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2), 5810(c)(3)(A)(iii), 5810(d)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1), 5550(a)(2), 5810(c)(3)(A)(iii), 5810(d)

Exact text from the filing

May 20, 2025, Petros Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of (i) the Company’s failure to maintain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), (ii) the Company’s failure to meet the minimum bid price of $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2), (iii) the Company’s low bid price pursuant to Nasdaq Listing Rule 5810(

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-051336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.